Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone

Lupus

Volumn 12, Issue 4, 2003, Pages 287-296

  Cortes Hernandez J ^a   Ordi Ros, J ^a   Labrador, M ^a   Segarra, A ^a   Tovar, J L ^a   Balada, E ^a   Vilardell Tarres, M ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Cyclophosphamide; Hypocomplementaemia; Lupus nephritis; Prognostic factors

Indexed keywords

CHLOROQUINE; CYCLOPHOSPHAMIDE; DNA ANTIBODY; DOUBLE STRANDED DNA; METHYLPREDNISOLONE; PREDNISONE;

ADOLESCENT; ADULT; AMENORRHEA; ANTIBODY TITER; ARTICLE; ATROPHY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG PULSE THERAPY; EARLY MENOPAUSE; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; HAIR LOSS; HERPES ZOSTER; HORMONE RELEASE; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPOCOMPLEMENTEMIA; KIDNEY FAILURE; KIDNEY TUBULE DISORDER; LEUKOPENIA; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; NAUSEA; PREDICTION; PRIORITY JOURNAL; PROTEINURIA; RELAPSE; SCHOOL CHILD; SIDE EFFECT; TREATMENT OUTCOME; VOMITING;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; AUTOANTIBODIES; CHILD; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; PROTEINURIA; PULSE THERAPY, DRUG; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 0345352680     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203303lu340oa     Document Type: Article

References (43)

1. Balow JE, Austin HA, Tsokos GC, Antonovych TT, Steinberg AD, Klippel JH. Lupus nephritis. Ann Intern Med 1987; 106: 79-84.
2. Boumpas DT, Austin HA, Vaughn EM et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992; 340: 741-745.
3. Conlon PJ, Fischer CA, Levesque MC et al. Clinical, biochemical and pathological predictors of poor response to intravenous cyclophosphamide in patients with proliferative lupus nephritis. Clin Nephrol 1996; 46: 170-175.
4. Dooley MA, Hogan S, Jennetee C, Falk R for the Glomerular Disease Collaborative Network. Cyclophosphamide therapy for lupus nephritis: Poor renal survival in black Americans. Kidney Int 1997; 51: 1188-1195.
5. Boumpas DT, Austin HA, Fessler BJ, Balow JE, Klippel JH, Lockshin MD. Systemic Lupus erythematosus: emerging concepts. Part I: renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease. Ann Intern Med 1995; 122: 940-950.
6. Steinberg AD, Gourley M. Cyclophosphamide in lupus nephritis. J Rheumatol 1995; 22: 1812-1815.
7. Cameron JS, Turner DR, Ogg CS, Williams DG, Lessof MH, Chantler C. Systemic lupus with nephritis: a long-term study. Q J Med 1979; 48: 1-24.
8. Austin HA III, Klippel JH, Ballow JE, Le Riche NGH, Steinberg AD, Plotz PH. Therapy of lupus nephritis. New Engl J Med 1986; 314: 614-619.
9. Felson DT, Anderson J. Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. New Engl J Med 1984; 311: 1528-1533.
10. McCune WJ, Golbus J, Zeldes W, Bohlke P, Dunne R, Fox DA. Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe lupus erythematosus. New Engl J Med 1988; 318: 1423-1431.
11. Mosca M, Pasquariello A, Tavoni A et al. Predictors of renal outcome in diffuse proliferative glomerulonephritis in systemic lupus erythematosus. Lupus 1997; 6: 371-378.
12. Houssiau FA, D'Cruz D, Vianna J, Hughes GR. Lupus nephritis: the significance of serological tests at the time of biopsy. Clin Exp Rheumatol 1991; 9: 345-349.
13. Austin III HA, Boumpas DT, Vaughn EM, Balow JE. High-risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients. Nephrol Dial Transplant 1995; 10: 1620-1628.
14. Yoo CW, Kim M-K, Lee HS. Predictors of renal outcome in diffuse proliferative lupus nephropathy: data from repeat renal biopsy. Nephrol Dial Transplant 2000; 15: 1604-1608.
15. Donadio JV, Hart GM, Bergstralh EJ, Holley KE. Prognostic determinants in lupus nephritis: a long-term clinicopathologic study. Lupus 1995; 4: 109-115.
16. Arce-Salinas CA, Villa AR, Martinez-Rueda JO et al. Factors associated with chronic renal failure in 121 patients with diffuse proliferative lupus nephritis: a case-control study. Lupus 1995; 4: 197-203.
17. Tan EM, Cohen AS, Fries J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
18. Austin HA III, Muenz LR, Joyce KM et al. Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med 1983; 75: 382-391.
19. Austin HA III, Muenz LR, Joyce KM, Antonovych TT, Balow JE. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 1984; 25: 689-695.
20. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chan CH, and the Committee on Prognosis Studies in SLE: derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630-640.
21. Aarden LA, Smeenk RJT. Measurements of antibodies specific for DNA. In: Lefkovits I, Pernis B (eds). Immunological Methods, Vol 2. Academic Press, New York, 1981, p 75.
22. Burlingame RW, Rubin RL. Subnucleosome structures as substrates in enzyme-linked immunosorbent assays. J Immunol Meth 1990; 134: 187-199.
23. Uwatoko S, Aotsuka S, Okawa M et al. Characterization of C1qbinding IgG complexes in systemic lupus erythematosus. Clin Immunol Immunopathol 1984; 30: 104-116.
24. Ordi-Ros J, Villarreal J, Monegal F, Sauleda S, Esteban I, Vilardell M. Anticardiolipin antibodies in patients with chronic hepatitis C virus infection: characterization in relation to antiphospholipid syndrome. Clin Diag Lab Immunol 2000; 7: 241-244.
25. Austin HA III, Klippel JH, Balow JE, Le Riche NGH, Steinberg AD, Plotz PH. Therapy of lupus nephritis. New Engl J Med 1986; 314: 614-619.
26. Boumpas DT, Austin HA III, Vaughan EM et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992; 340: 741-745.
27. Bansal VK, Beto JA. Treatment of lupus nephritis: a meta-analysis of clinical trials. Am J Kidney Dis 1997; 29: 193-199.
28. Dawisha SM, Yarboro CH, Vaughan EM, Austin HA III, Balow JE, Klippel JH. Outpatient monthly oral bolus cyclophosphamide therapy in systemic lupus erythematosus. J Rheumatol 1996; 23: 273-278.
29. Chan TM, Li FK, Wong RWS, Chan KW, Cheng IKP. Sequential therapy for diffuse proliferative and membranous lupus nephritis: cyclophosphamide and prednisolone followed by azathioprine and prednisolone. Nephron 1995; 71: 321-327.
30. Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J, Rohde RD, for the Lupus Nephritis Collaborative Study Group. Factors predictive of outcome in severe lupus nephritis. Am J Kidney Dis 2000; 35: 904-914.
31. Ioannidis JPA, Boki KA, Katsorida ME et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 2000; 57: 258-264.
32. Pablos JL, Gutierrez-Millet V, Gomez-Reino JJ. Remission of lupus nephritis with cyclophosphamide and late relapses following therapy withdrawal. Scand J Rheumatol 1994; 23: 142-144.
33. Moroni G, Quaglini S, MacCario M, Banfi G, Ponticelli C. Nephritic flares are predictors of bad long-term outcome in lupus patients. Kidney Int 1996; 50: 2047-2053.
34. Austin HA III, Muenz LR, Joyce KM, Antonovych TT, Balow JE. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 1984; 25: 689-695.
35. Berden JHM. Lupus nephritis. Kidney Int 1997; 52: 538-558.
36. Esdaile JM, Abrahamowicz M, Mackenzie T, Hayslett JP, Kashgarian M. The time-dependence of long-term prediction in lupus nephritis. Arthritis Rheum 1994; 37(3): 359-368.
37. Goulet JR, Mackenzie T, Levinton C, Hayslett JP, Ciampi A, Esdaile JM. The long-term prognosis of lupus nephritis: The impact of disease activity. J Rheumatol 1993; 20: 59-65.
38. Ginzler EM, Felson DT, Anthony JM, Anderson JJ. Hypertension increases the risk of renal deterioration in systemic lupus erythematosus. J Rheumatol 1993; 20: 1694-1700.
39. Clark WF, Moist LM. Management of chronic renal insufficiency in lupus nephritis: Role of proteinuria, hypertension and dyslipemia in the progression of renal disease. Lupus 1998; 7: 649-653.
40. Esdaile JM, Federgreen W, Quintal H, Suissa S, Hayslett JP, Kashgarian M. Predictors of one-year outcome in Lupus Nephritis: The importance of renal biopsy. Q J Med 1991; 295: 907-918.
41. Whiting-O'Keefe Q, Henke JE, Shearn MA, Hooper J, Biava CG, Epstein WV. The information content from renal biopsy in systemic lupus erythematosus: stepwise linear regression analysis. Ann Intern Med 1982; 96: 718-723.
42. Ciruelo E, De la Cruz J, Lopez I, Gomez-Reino JJ. Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide. Arthritis Rheum 1996; 39: 2028-2034.
43. Ponticelli C, Moroni G. Flares in lupus nephritis: Incidence, impact on renal survival and management. Lupus 1998; 7: 635-638.